E
Lexeo Therapeutics, Inc. LXEO
$4.77 $0.8421.37% NASDAQ
Recommendation
Prev Close
$3.93
Volume
1,111,134
Avg Vol (90D)
606,740
Market Cap
$130.46M
Dividend & Yield
--
52-Week Range
$1.45 - $19.50
P/E (TTM)
--
EPS (TTM)
-$3.09
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Pharma Frenzy: Volatility Ignites Biotech Sector
3/25/2025 - MarketBeat
Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell ...
5/1/2025 - GuruFocus
Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell ...
5/1/2025 - GuruFocus
Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
5/1/2025 - Globe Newswire
Adage Capital Partners GP L.L.C. Sells 388,121 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)
4/29/2025 - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages
4/28/2025 - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by D1 Capital Partners L.P.
4/26/2025 - MarketBeat
Walleye Capital LLC Takes $407,000 Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)
4/24/2025 - Ticker Report
Altium Capital Management LLC Takes $2.67 Million Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)
4/20/2025 - MarketBeat
Altium Capital Management LLC Purchases Shares of 405,000 Lexeo Therapeutics, Inc. (NASDAQ:LXEO)
4/18/2025 - Ticker Report
Chardan Capital Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $22.00
4/10/2025 - MarketBeat
Lexeo Therapeutics' (LXEO) Buy Rating Reiterated at HC Wainwright
4/10/2025 - MarketBeat
Lexeo Therapeutics price target lowered by $3 at Chardan, here's why
4/7/2025 - The Fly
Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials
4/7/2025 - Benzinga
Lexeo Therapeutics (LXEO) Reports Positive Interim Results for LX2006 in FA Cardiomyopathy
4/7/2025 - GuruFocus
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia ...
4/7/2025 - GuruFocus
Lexeo Therapeutics announces 'positive' Interim Phase 1/2 data for LX2006
4/7/2025 - The Fly
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
4/7/2025 - Globe Newswire
lexeo locks pivotal trial plan clinical data pump prospects cardiac gene therapy
4/7/2025 - FierceBiotech.com - Biotech
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Buy" by Brokerages
4/3/2025 - MarketBeat
What is Chardan Capital's Forecast for LXEO FY2025 Earnings?
3/29/2025 - MarketBeat
Q1 EPS Forecast for Lexeo Therapeutics Lifted by Analyst
3/29/2025 - MarketBeat
FY2025 Earnings Estimate for LXEO Issued By Leerink Partnrs
3/28/2025 - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Lexeo Therapeutics (NASDAQ:LXEO)
3/27/2025 - MarketBeat
Q1 Earnings Forecast for LXEO Issued By Leerink Partnrs
3/27/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$105.14M
EBIT (TTM)
-$105.77M
Net Income (TTM)
-$98.33M
Balance Sheet
Total Assets (Q)
$146.94M
Total Debt (Q)
$9.92M
Total Liabilities (Q)
$30.10M
Book Value Per Share (Q)
$3.53
Cash Flow
Cash from Operations (TTM)
-$81.15M
Cash from Investing (TTM)
-$94.08M
Cash from Financing (TTM)
$88.78M
Net Change in Cash (TTM)
-$86.45M
Filings
Filing Date
Monday, March 24, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
--
7-Day Total Return
38.60%
30-Day Total Return
55.92%
60-Day Total Return
-17.85%
90-Day Total Return
-25.47%
Year to Date Total Return
-28.94%
1-Year Total Return
-61.46%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $1.45
52-week High
Jul 11, 2024 - $19.50
Valuation
Market Cap
$130.46M - Micro Cap
Enterprise Value
$18.87M
Price/Sales (TTM)
--
Price/Book (Q)
1.11
Dividends and Shares
Shares Outstanding
33.08M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.lexeotx.com
Phone Number
212 547 9879
Address
345 Park Avenue South
New York, NY 10010
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006... more
NASDAQ 05/01/2025 2:46PM Eastern Quotes delayed